Alnylam Pharmaceuticals (ALNY) Research & Development (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) recorded Research & Development of $413.13 million in Q2 2026, up 27.7% from $323.62 million a year earlier and up 13.2% from the prior quarter.
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Research & Development (2009 - 2026) Analysis & Trends
On a TTM basis, Alnylam Pharmaceuticals' Research & Development came in at $1.51 billion as of Jun 30, 2026, up 30.1% year-over-year; for FY2025, it came in at $1.32 billion, up 17.2% from FY2024.
- Annual Research & Development has increased for five straight years, with a five-year compound annual growth rate of 15.0% (FY2020 to FY2025).
- Across earlier years, Research & Development came in at $1.13 billion in FY2024 (+12.1%), $1 billion in FY2023 (+13.7%), $883.02 million in FY2022 (+11.5%) and $792.16 million in FY2021 (+21.0%).
- The Q2 2026 figure is the highest quarterly Research & Development in data going back to Q2 2009.
- On a year-over-year basis, Research & Development has increased for 17 consecutive quarters, with growth averaging 18.8% over the last eight quarters.
- Peak year-over-year performance for Research & Development in the last five years was growth of 37.6% in Q1 2026, against a decline of 8.6% in Q1 2022 at the low end.
- Per Business Quant, the preceding three quarters came in at $364.87 million (Q1 2026), $372.22 million (Q4 2025) and $358.81 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.54 Bn | 572.07 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 467.01 Bn | 440.17 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.16 Bn | 321.59 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 277.56 Bn | 233.43 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 258.23 Bn | 231.79 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 224.14 Bn | 179.54 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 187.30 Bn | 161.42 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.47 Bn | 110.41 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.31 Bn | 105.31 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Alnylam Pharmaceuticals | 34.23 Bn | 22.28 Bn | 992.69 Mn | 413.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 413.13 Mn |
| Mar 31, 2026 | 364.87 Mn |
| Dec 31, 2025 | 372.22 Mn |
| Sep 30, 2025 | 358.81 Mn |
| Jun 30, 2025 | 323.62 Mn |
| Mar 31, 2025 | 265.12 Mn |
| Dec 31, 2024 | 300.17 Mn |
| Sep 30, 2024 | 270.93 Mn |
| Jun 30, 2024 | 294.14 Mn |
| Mar 31, 2024 | 261.00 Mn |
| Dec 31, 2023 | 272.14 Mn |
| Sep 30, 2023 | 253.18 Mn |
| Jun 30, 2023 | 248.53 Mn |
| Mar 31, 2023 | 230.57 Mn |
| Dec 31, 2022 | 262.04 Mn |
| Sep 30, 2022 | 245.37 Mn |
| Jun 30, 2022 | 205.71 Mn |
| Mar 31, 2022 | 169.89 Mn |
| Dec 31, 2021 | 229.05 Mn |
| Sep 30, 2021 | 194.57 Mn |
API Access
Alnylam Pharmaceuticals Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=ALNY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "ALNY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=ALNY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();